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Recurrence of dense deposits in transplanted kidney: H. Serum
complement and nephritic factor profiles. Dense deposit disease
of the kidney is a rare form of chronic glomerulonephritis fre-
quently associated with serum complement abnormalities (low
C3 levels) and a circulating C3 convertase activator of the alter-
native pathway, the C3 nephritic factor (NE). Eleven patients
with end-stage dense deposit disease underwent kidney trans-
plantation. Of the 11, 7 had pretransplant low C3 and NF. In the
posttransplant period, persisting low C3 levels were associated
with persisting NF, although not quantitatively so. The original
glomerular lesion recurred in the graft within 6 months in 9 of 11.
Of these 9, 2 had no complement abnormalities either prior to or
after transplantation. Pretranspiant complement abnormalities
were rapidly corrected in 4 of 7 patients whether or not recur-
rence of the original lesion occurred. Thus, serum complement
profiles before and after transplantation are neither predictive
nor indicative of recurrence.
Récidive des dépôts denses dans le rein transplanté: II. Evolu-
tion du complement et du facteur néphritique seriques. La malad-
ie des dépôts denses est une forme rare de glomdrulonéphi-ite
chronique fréquemment associée a des anomalies du com-
plément sérique (baisse de C3) et a la presence d'un activateur
circulant de Ia C3 convertase de Ia voie alterne, Ic facteur
néphritique (NF). Onze malades atteints de maladie des dépóts
denses ont subi une transplantation rénale. Sept d'entre eux
avaient des valeurs basses de C3 et de NF avant transplantation.
Dans Ia période consecutive a Ia transplantation, les valeurs
basses de C3 ont etc associées a Ia persistance du NF, quoique
sans relation quantitative. La lesion glomerulaire initiale a réci-
dive dans le greffon dans les 6 mois pour 9 de ces 11 malades.
Deux parmi ces 9 n'avaient pas d'anomalie du complement ni
avant ni apres Ia greffe. Les anomalies du complement antéri-
eures a Ia transplantation ont etC rapidement con-igées chez 4
malades parmi 7, indCpendamment de Ia rCcidive de Ia lesion mi-
tiale. Ainsi l'évolution du complement serique avant et aprCs
transplantation ne permet ni de prévoir ni d'affirmer Ia rCcidive.
Dense deposit disease is associated with serum
complement abnormalities highly suggestive of a
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diffuse, predominantly intravascular activation of
the alternative pathway of the complement system
[1]. Many of these patients have a substance in their
serum capable of initiating in vitro the formation of
an alternative pathway C3 convertase, the so-called
C3 nephritic factor (NF) [2, 3]. Immunofluorescence
studies of the diseased kidneys have revealed C3
deposits without demonstrable early classical path-
way components, Clq and C4, and essentially no
immunoglobulin G, A, or M, [4] an aspect compat-
ible with a local activation of the alternative path-
way.
A causal relationship between the serologic ab-
normalities and kidney disease has been suggested
[3]. Evidence for this has stemmed primarily from
the observation of patients with partial lipo-
dystrophy (PLD) who often harbor NF in their
serum, have a low C3 level with an accelerated ca-
tabolism of this component [6], and appear to fre-
quently develop nephritis, mostly of the dense de-
posit type [7, 8]. Data indicate that nephritis is ap-
parent only in those PLD patients whose serum
contains NF [8]. Because indirect evidence sug-
gests that the complement abnormalities precedes
the appearance of renal disease (indeed, PLD devel-
ops long before nephritis), it has been proposed that
low levels of serum C3 or the presence of NF, or
both might predispose these patients to the develop-
ment of nephritis.
We have shown in a previous paper [9] (Kidney
Int, this issue) that recurrence of dense deposits in
the grafts is the primary event followed in time by
local complement deposition, mostly in the mesan-
gial area. We wish to report here on observations of
the complement abnormalities in these same pa-
tients. From this study, the presence of detectable
NF or low levels of C3 were not found to be a pre-
requisite for the development of dense deposits in
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the kidney graft, nor does recurrence lead to com-
plement abnormalities.
Methods
Normal human serum. Sera samples from 20
blood donors were clotted at room temperature for
2 hours, pooled, and stored in small aliquots at
800 C. The pooled sera served as the source of
normal human serum (NHS) in the NF assay and as
reference for the quantitation of the complement
components.
Patient sera. Sera samples from patients were
collected in the same way and stored frozen at
—20° C. The patients are described in the preceding
article [9] (this issue).
Antisera. Goat antisera to human C3 and to factor
B were obtained from Atlantic Antibodies (Port-
land, Oregon). Rabbit antisera to human C4 and C9
were purchased from Behring Laboratories (Paris).
Antiserum to human C5 was obtained by immuniza-
tion of rabbits with a highly purified human C5 prep-
aration, as previously described [1]. Monospecific
goat antihuman properdin was purchased from At-
lantic Antibodies.
Quantitation of serum complement components.
Levels of C3, C4, CS, C9, factor B, and beta-i-H
were measured by electroimmunoprecipitation [10]
in 1% agarose (Behring) and veronal Tris glycine
buffer (ph, 8.8), containing 0.01 M EDTA. Results
are expressed as a percent of the NHS pool. Nor-
mal values (from 20 donors) were: C3,  70; C4, 
50; C5,  60; C9,  60; factor B,  55. The normal
serum pooi gave a value of 95 mg of C3 per 100 ml in
reference to a commercial standard (Hyland Labo-
ratories).
NF assay. The test serum was mixed with NHS
in the presence of EGTA and magnesium incubated
for 45 mm at 37° C, and the mixture was submitted
to two-dimensional electrophoresis as previously
described [11]. The control consisted of a mixture
of NHS and test serum in the presence of EDTA.
The exact reaction mixture consisted of 40 l of
both test and normal serum, 10 p1 of EGTA (0.1 M;
ph, 7.2), and 10 p1 of magnesium chloride (10 mM).
The control was made of 40 p1 of each sera with 20
p1 of EDTA (0.1 ph, 7.2). The percentage of C3
conversion obtained in vitro was calculated accord-
ing to the following formula:
% C3 conversion =
EGTA area of anodal peak — EDTA anodal peaktotal area total area
Percent of C3 conversion in vitro was converted to
arbitrary NF units, 100% conversion being equal to
100 U. Figure 1 shows the precipitation peaks of a
test serum yielding 58 NF U. One patient's NP, af-
ter partial purification (see infra), was assayed for
its ability to stabilize the labile C3 convertase of the
alternative pathway on red cells [12].
Partial purification of NF. NP was partially puri-
fied from the pseudoglobulin fraction of NF-posi-
tive sera, which was applied to a DEAE cellulose
column in 0.02 M phosphate (ph, 7.00) and sequen-
tially to a SP C25 resin in 0.02 M phosphate (ph,
7.2). All the column fractions were tested for IgG by
electroimmunoassay after carbamylation and for C3
convertase activity with the NF assay. During such
fractionation, NF can be separated from activated
properdin () (Fig. 2), as has been described [12,
13].
Results
The levels of NF and C3 before and after trans-
plantation are shown in Table 1.
NF-positive patients (patients 1, 4—8, 10). Seven
patients had detectable NP at the time of trans-
plantation. C3 levels at this time were less than 30%
(28 mg/100 ml) in all seven. NP activity declined
thereafter so that in four of the seven patients no
such activity could be detected within 2 months. In
these 4 patients C3 levels rose to normal or near
normal values within the same period of time. In
patient 10, NF activity remained weakly positive at
16 months, whereas low C3 levels persisted. At 42
months, NF was no longer detected, and C3 con-
centration was normal. Patients 4 and 8 had persist-
ent NF together with low C3 levels 30 and 16 months
after grafting, respectively.
NF-negative patients (patients 2, 3, 9, 11). Four
patients did not have detectable NF activity before
transplantation. NP was never detected in any of
them after transplantation. C3 levels of these pa-
tients were greater or equal to 60% (58 mg/100 ml) at
the time of grafting. They remained so or became
transiently elevated in all four.
Levels of B, C4, C5, C9, and beta-i-H before and
after transplantation (Table 2). These were mea-
sured sequentially in four patients. Results showed
essentially normal C4; low-normal CS levels, rising
to over normal levels; and high levels of C9, rising
between 2 and 10 times normal values after trans-
plantation. Beta-i-H, a protein recently described
as a modulator of C3b inactivator activity [14]
showed no abnormalities. Factor B levels were nor-
mal except for patient 5, who had low B levels be-
Gradient
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Fig. 2. Separation of nephritic factor (NF) from activated properdin. Chromatography of a NF-positive serum on a SPC-25-Sephadex
resin. The column is loaded with the concentrated NF containing effluent of a preliminary DEAE-cellulose column (see text). Closed
circles with broken lines (• •) denote IgG concentration; Open circles with straight lines (O——O) denote alternative pathway C3
convertase activity. Antigenic properdin (ouchterlony) was found in the second C3 converting peak. The first C3 converting peak
contains NF [13].
fore transplantation which returned to normal val-
ues after transplantation.
Kinetics of complement alteration after trans-
plantation (Fig. 3). In four patients we could study
the kinetics of the early diminution or disappearance
of NF activity in the immediate posttransplantation
period, together with C3 and factor B levels. Three
patients (patient 1, second transplantation; and pa-
tients 5 and 6) received an immunosuppressive regi-
men consisting of a combination of azathioprine (3
mg/kg) and corticosteroid (5 mg/kg). The dosage of
steroids was gradually diminished, so that by day 28
their daily dosage was 0.25 mg/kg. Patient 7 re-
ceived azathioprine alone until day 23. In three pa-
tients (patient 1, second transplantation; and patients
5 and 6), NF activity declined rapidly, so that by day
10, C3 convertase activity was near nondetectable
levels. C3 levels readily increased in patients 1 and
5, but it increased at a much slower pace in patient
6. In patient 7, although NF activity definitely de-
creased from 80 to 20 U by day 8, C3 levels did not
rise. By day 23, C3 levels were unchanged, and NF
activity was up to 40 U. At this point, steroids ther-
apy was begun. Twelve days later, patient 7's NF
was down to undetectable levels, and C3 levels
reached normal value 25 days thereafter.
Fractionation of a posttransplantation NF-nega-
tive serum. Because it had been said that allotrans-
plantation was sometimes associated with the ap-
pearance in the serum of a factor inhibiting C3 con-
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Fig. 1. Quantitation of nephritic factor (NF) activity by two-dimensional electrophoresis (method of Laurel!). NHS alone in EGTA
magnesium gives a percentage of C3 conversion less than or equal to that of the control EDTA mixture (2 left peaks). The test reaction
mixture (NF + normal serum in EGTA magnesium) shows 70% C3 conversion. The control mixture (NF + normal serum in EDTA)
gives 12% C3 conversion. This value is subtracted from the test mixture. The final result for NF activity in this case is 58 U.
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Table 1. Early and late posttransplantation C3 and nephritic factor (NF) values and incidence of recurrence of dense deposits in the
kidneya
Recurrence
Patient
no.
Before
transplantation
2 Months
after graft Late samples
1st positive
biopsy
1b C3 25 90 + 2mo.
NF 40 10
2 C3 60 250 110 (72 mo.) + 3mo.
NF 10 10 10
3 C3 75 115 150 (12 mo.) 130 (14 mo.) —l9mo.
NF 10 10 10 10
4 C3 20 40 10(30 mo.) + 6wk.
NF 40 17 20
5 C3 5 100 106 (12 mo.) + 6 mo.
NF 90 10 10
6 C3 10 80 +3wk.
NF 30 10
7 C3 5 110 120 (3 mo.) + 3 wk.
NF 67 10 10
8 C3 20 — 25 (16 mo.) + 6mo.
NF 35 — 40
9 C3 135 — 140 (24 mo.) 120 (84 mo.) + 6mo.
NF 10 — 10 10
10 C3 30 54 30(16 nio.) 100 (42 mo.) + 6mo.
NF 83 26 21 10
11 C3 110 120 130 2.5 mo.
NF 10 10 10
aResults for C3 are expressed as percent of a NHS (normal human serum) pool (ni + 70); those for NF are expressed as NF units
(nl 10) (See Methods). ND = not determined.
bThjs patient underwent two transplantations. No data beyond 2 weeks are available for the second transplantation because of acute
rejection.
version in vitro [15], we asked the question whether
such a factor or whether other inhibitor(s) [16]
could account for the disappearance of NF activity
after transplantation. Fractionation of patient 7's
sera, both before and after transplantation, was per-
formed as outlined in Methods. Results of this ex-
periment is presented in Table 3. No C3 converting
activity could be found in the fractioned post-
transplantation NF-negative serum, whereas the
pretransplant NF-positive specimen yielded in-
creased amounts of C3 converting activity upon
fractionation, as had been described [13].
Correlation between recurrence of dense deposits
and complement profiles (Tables 1 and 4). Dense
deposits were found in biopsy specimens of trans-
planted kidneys in seven of seven initially NF-
positive, low-C3 patients. Four of these seven had
shown rapid disappearance of NF (within 2 months)
and normalization of C3 levels (patients 1, 5-7). The
other three had persisting complement abnormalities
for at least 16 months (patients 4, 8, and 10). It is of
note that patient 5, whose NF was rapidly suppressed
after transplantation, has clinically patent PLD.
Two of the four NF-negative patients (patients 2
and 9) had recurrent dense deposit disease at the
first transplant biopsy obtained at 3 and 6 months,
respectively. Two patients of this group remain free
of deposits as of the last biopsy (19 and 2.5 months,
Table 2. Complement levels before (T0) and after transplantation (2 months) in four patientsa
Patient
no. To
C4
2 mo. T0
CS
2 mo. T0
C9
2 mo. T0
B
2 mo.
B
T0
1H
2 mo.
3 95 105 120 450 300 1000 100 175 — —
5 85 100 60 250 180 250 48 94 130 150
6 80 100 85 190 190 240 100 100 62 70
7 110 160 60 270 180 560 100 350 70 90
Normal
range 50 to 130% 60to 160% 60 to 200% 55%
aResults are expressed as percent of the NHS (normal human serum) pool (See Methods)
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respectively, for patients 3 and 11). Progression of
the dense deposits was seen in two patients with
persistingly NF-positive findings (patients 4 and 10)
[9]. A similar progression, however, was seen also
in patient 9, who never had complement abnormal-
ities. Thus, there are no clear correlations between
circulating NF and the extension of the recurrent
lesion. In summary, recurrence occurred in seven
of seven patients with pretranspiant NF whether or
not the associated serologic abnormalities had
rapidly been corrected after transplantation. Two
patients (patients 2 and 9) with no complement
abnormalities before transplantation have also
shown recurrence. The late complement profiles
have remained or returned to normal despite patent
local recurrence in seven patients (Table 1).
Discussion
Recurrence of the intramembranous dense depos-
its following renal transplantation has been pre-
viously reported [18, 22]. The high incidence of re-
currence which we confirm and extend on a larger
group of patients and the complement abnormalities
are two prominent features characteristic of DDD.
In view of the possible pathogenic roles sug-
gested for hypocomplementemia and NF [9], it
seemed of interest to study the alteration of the
complement system after transplantation and its
possible bearings to recurrence of dense deposits.
Suppression of NF after transplantation: A pos-
sible role for steroids. Disappearance of NF after
transplantation occurred in five of seven initially
NF-positive patients, and rapidly so (within 2
months) in four. Inhibitors of C3 conversion such as
described by Spitzer et al [15] and us [16] which
might have accounted for the loss of NF activity
were not found (Table 3). The C3 convertase assay
that we used is known to be poorly sensitive, so that
it may be argued that nondetection of NF activity
with such assay cannot be held as fairly indicating
NF disappearance. For this reason, we assayed the
IgG-DEAE fractions of patient 7's sera for its ability
to stabilize the labile cell-bound C3 convertase of the
alternative pathway [12]. In such an assay, 16 j.tg of
the DEAE-IgG preparation of patient 7's pre-
transplant serum stabilized 10 hemolytic sites; 1200
tg of patient 7's posttransplantation IgG had no
such stabilizing effect. Thus, "NF-negative" serum
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Fig. 3. A-D C3 factor, and nephritic factor (NF) activity in four patients within the first 2 months following transplantation. Data for
patient 1 are those of his second transplantation. He had been anephric for over 12 months before his second transplantation. The
shaded areas indicate the normal range.
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contains approximately 100 times less NF than its
pretranspiantation counter part did.
Corticosteroids seem to play a major role in the
suppression of NF activity, a fact already apparent
in nontranspianted patients [171, and further sug-
gested by the observation of our patient 7 (Fig. 3). If
steroids may suppress NP, they do not always have
such an effect since three of our patients had per-
sistently low levels of C3 convertase activity al-
though they received essentially the same immuno-
suppressive therapy. Corticosteroid-suppressible
NF also did not reappear in the susceptible patients
even though their steroid dosage had been de-
creased to less than 0.3 mg/kg/day. The behavior of
NP after transplantation and its relative sensitivity
to corticosteroids is in accordance with its immuno-
globulin nature [23, 261. The fact that the IgO mole-
cules with NF activity often are monoclonal in
structure would further help account for their corti-
costeroid sensitivity.
NF and C3 levels. The rise in C3 levels that we
have seen in five of seven patients with low pre-
transplantation C3 levels, and the very rapid rise
(within 2 months) found in four of these patients,
seems associated with suppression of NF activity.
Conversely, the persistence of low C3 levels is
found in those patients in whom C3 convertase ac-
tivity persists. This qualitative negative correlation
is clearly indicated in Table 1: NF levels greater
than 10 U in one given patient is associated with low
C3 levels, whereas a NF value of 10 U in a patient
with previously higher levels of NF is associated
with normal or elevated C3. This "threshold" of 10
70.
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Table 3. Fractionation of one NF-positive and one NF-negative
serum sample from the same patient (patient 7)
NF
units
IgG
concentration
mg/mi NF/lgG
NF positive
Whole serum
Exclusion peak DEAE
NF negative
Whole serum
Exclusion peak DEAE
90
95
10
8
18.40
10.40
14.40
12
4.9
9.12
0,69
0.66
RAfter concentration
Table 4. Complement profiles before transplantation and
incidence of recurrence
Normal complement Low complement
Recurrence 2 7
No recurrence 2 0
As indicated in Table 1, all patients with low C3 had detect-
able NF activity.
U would not be significant in a randomly selected
horizontal" population since normal sera can give
values of C3 conversion as high as 15% in our labo-
ratory. The longitudinal study provided here by the
followup of individual transplanted patients, how-
ever, suggests that such a percent threshold value is
significant. That one cannot establish a reciprocal
quantitative relationship between NF levels and C3
levels is also clear from these observations, a fact
already stressed by Vallota et al, in their studies of a
group of steroid-treated nontranspianted patients
17]. Whatever the reasons for such nonlinear recip-
rocal correlations, the fact remains that in these
transplanted patients a low C3 level appears as a
marker of detectable circulating NF. The inverse
qualitative correlation between C3 levels and NF is
also found in nonsteroid-treated, nontranspianted
patients with dense deposit disease: C3 was normal
in 2 NF-negative and was less than 20% in 14 NF-
positive patients (Leibowitch and Halbwachs, un-
published observation).
Incidence of recurrence and complement pro-
files. Recurrence of deposits has occurred rapidly in
seven of seven patients with pretransplant low C3
and NF. It also has been seen, however, in two of
four patients without any complement abnormali-
ties. Persisting hypocomplementemia after trans-
plantation in our series and in series previously
reported [19-2 1] was always associated with recur-
rence, but in our patients it is clear that normal or
rapidly normalized complement profiles were also
associated with recurrence. Thus, there are no
necessary connections between recurrence and the
serologic complement abnormalities. The develop-
ment of dense deposits is not always associated
with low C3 and detectable NF, nor does recurrence
necessarily lead to low C3 levels. From a patho-
genetic point of view, our data suggests that a high
rate of intravascular activation of complement via
NF is not an obligatory factor for the development
of the lesions. Conversely, dense deposits in the
kidney cannot be held responsible for the comple-
ment abnormalities [27] (and our anephric patient
no. 1), which seem, for most, related to the presence
of NF. Thus, although the high rate of recurrence
indicates the continued presence of some "ne-
phritogenic" process, the serum complement ab-
normalities are not a fair indicator of such persistent
host factor(s) [19].
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